Patents by Inventor Robert D'Amato

Robert D'Amato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11609892
    Abstract: A computing machine stores a tree structure representing a hierarchical organization. The tree structure comprises a command node and a plurality of domain nodes below the command node. The computing machine leverages the tree structure to generate a multi-domain operational plan.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: March 21, 2023
    Assignee: Raytheon Company
    Inventors: Judy Y. Amato, Laura D. Strater, Michael H. Lewis, Terry L. Keeney, Vincent A. Pascente, Jared B. Dorny, Michael A. Young, David B. Jenks, Robert T. Stratton, Michael P. Sica
  • Publication number: 20220403472
    Abstract: This invention provides methods for near-instantaneously separating cells that have undergone RNA guided genome modifications into pre-templated instant partitions (PIPs) and using the PIPs to associate the guide RNAs with the gene expression level changes that resulted from the genome modification.
    Type: Application
    Filed: May 18, 2022
    Publication date: December 22, 2022
    Inventors: Kristina Fontanez, Iain Clark, Christopher D'Amato, Catherine Kugler, Robert Meltzer
  • Publication number: 20220267761
    Abstract: Methods to emulsify cells and/or mRNA with reverse transcriptase at a temperature such that the reverse transcriptase begins making cDNA during the emulsification
    Type: Application
    Filed: May 10, 2022
    Publication date: August 25, 2022
    Inventors: Kristina Fontanez, Robert Meltzer, Yi Xue, Christopher D'amato, Sepehr Kiani
  • Publication number: 20220235416
    Abstract: This disclosure provides methods and systems for single-cell analysis, including single-cell transcriptome analysis, of target cells without microfluidic devices. The disclosed methods involve the use of template particles to template the formation of monodisperse droplets to generally capture a single target cell from a population of cells in an encapsulation, derive a plurality of distinct mRNA molecules from the single target cell, and quantify the distinct mRNA molecules to generate an expression profile.
    Type: Application
    Filed: April 11, 2022
    Publication date: July 28, 2022
    Inventors: Kristina Fontanez, Robert Meltzer, Yi Xue, Christopher D'amato, Sepehr Kiani
  • Patent number: 10286032
    Abstract: Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these peptide analogs and uses thereof.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: May 14, 2019
    Assignee: Children's Medical Center Corporation
    Inventors: Avner Adini, Robert D'Amato
  • Patent number: 9789199
    Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: October 17, 2017
    Assignee: Children's Medical Center Corporation
    Inventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
  • Patent number: 9782489
    Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: October 10, 2017
    Assignee: Children's Medical Center Corporation
    Inventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
  • Patent number: 9597371
    Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: March 21, 2017
    Assignee: Children's Medical Center Corporation
    Inventors: Avner Adini, Robert D'Amato
  • Publication number: 20160375144
    Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
  • Publication number: 20160361428
    Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.
    Type: Application
    Filed: August 26, 2016
    Publication date: December 15, 2016
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
  • Patent number: 9446140
    Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: September 20, 2016
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
  • Publication number: 20160136292
    Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.
    Type: Application
    Filed: January 25, 2016
    Publication date: May 19, 2016
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Ofra BENNY-RATSABY, Robert D'AMATO, Judah FOLKMAN
  • Patent number: 9272050
    Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: March 1, 2016
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
  • Publication number: 20150359842
    Abstract: Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these peptide analogs and uses thereof.
    Type: Application
    Filed: June 22, 2015
    Publication date: December 17, 2015
    Inventors: Avner Adini, Robert D'Amato
  • Patent number: 9090707
    Abstract: Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these pep tide analogs and uses thereof.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: July 28, 2015
    Assignee: Children's Medical Center Corporation
    Inventors: Avner Adini, Robert D'Amato
  • Publication number: 20150104406
    Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.
    Type: Application
    Filed: September 24, 2014
    Publication date: April 16, 2015
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
  • Patent number: 8865151
    Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: October 21, 2014
    Assignee: Children's Medical Center Corporation
    Inventors: Ofra Benny-Ratsaby, Robert D'Amato, Judah Folkman
  • Publication number: 20140301969
    Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 9, 2014
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
  • Patent number: 8790634
    Abstract: The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: July 29, 2014
    Assignee: Children's Medical Center Corporation
    Inventors: Ofra Benny-Ratsaby, Robert D'Amato, Takeru Yoshimura
  • Publication number: 20140194358
    Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.
    Type: Application
    Filed: October 28, 2013
    Publication date: July 10, 2014
    Applicant: Children's Medical Center Corporation
    Inventors: Avner Adini, Robert D'Amato